Neurocrine Biosciences (NBIX) Selling, General & Administrative (2010 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Selling, General & Administrative (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.95 Bn | 625.20 Bn | 17.26 Bn | 6.43 Bn |
| 2 | AbbVie | 441.39 Bn | 434.82 Bn | 12.70 Bn | 3.63 Bn |
| 3 | Merck | 366.72 Bn | 359.58 Bn | 12.21 Bn | 2.90 Bn |
| 4 | Novartis Ag | 266.68 Bn | 258.99 Bn | 11.24 Bn | -3.24 Bn |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | 3.41 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -2.87 Bn |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 110.21 Mn |
| 8 | Incyte | 25.50 Bn | 20.96 Bn | 1.57 Bn | 351.74 Mn |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | 206.70 Mn |
| 10 | Neurocrine Biosciences | 15.60 Bn | 15.21 Bn | 935.80 Mn | 439.70 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 439.70 Mn |
| Mar 31, 2026 | 318.50 Mn |
| Dec 31, 2025 | 301.80 Mn |
| Sep 30, 2025 | 291.60 Mn |
| Jun 30, 2025 | 286.30 Mn |
| Mar 31, 2025 | 276.50 Mn |
| Dec 31, 2024 | 287.80 Mn |
| Sep 30, 2024 | 234.30 Mn |
| Jun 30, 2024 | 242.00 Mn |
| Mar 31, 2024 | 243.10 Mn |
| Dec 31, 2023 | 218.90 Mn |
| Sep 30, 2023 | 204.20 Mn |
| Jun 30, 2023 | 221.80 Mn |
| Mar 31, 2023 | 242.70 Mn |
| Dec 31, 2022 | 182.90 Mn |
| Sep 30, 2022 | 186.30 Mn |
| Jun 30, 2022 | 182.80 Mn |
| Mar 31, 2022 | 200.70 Mn |
| Dec 31, 2021 | 156.50 Mn |
| Sep 30, 2021 | 154.60 Mn |